News & Filings

INDGN \u2014 Recent Activity

5 items in the last 14 days

AI Summary

As an Indian retail investor, you should be aware that Indegene Ltd has been reporting robust revenue growth, driven by strategic acquisitions and partnerships, such as its recent collaboration with Datavant. The company's financial performance has been strong, with notable growth in recent quarters and full-year 2025. This information may be relevant to your investment decisions, as it reflects the company's ongoing performance and growth prospects.

Lownews· GuruFocus.com
3 Feb

Indegene Ltd (NSE:INDGN) Q3 2026 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ...

Indegene Ltd (NSE:INDGN) reports strong revenue growth and strategic advancements, despite facing short-term profitability challenges.

Click to open →

Lownews· TipRanks
20 Nov

Cingulate price target lowered to $16 from $17 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and keeps a Buy rating on the shares after meeting with its management to discuss Q3 results. The company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, though the firm is adjusting its model on expectation that Cingulate may choose to raise capital during the next 6 to 12 months, the analyst tells investors in a research note.TipRanks

Click to open →

Lownews· GuruFocus.com
8 Nov

Indegene Ltd (NSE:INDGN) Q2 2026 Earnings Call Highlights: Strategic Acquisitions and Revenue ...

Indegene Ltd (NSE:INDGN) reports strong revenue growth and strategic acquisitions, while navigating margin challenges and segmental shifts.

Click to open →

Lownews· Clinical Trials Arena
22 Sept

Datavant and Indegene partner to improve trial subject recruitment

The partnership focuses on studies concerning rare diseases and other complex ones.

Click to open →

Lownews· GuruFocus.com
1 May

Indegene Ltd (NSE:INDGN) Full Year 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Indegene Ltd (NSE:INDGN) reports a 9.6% revenue increase and a 100% dividend, while navigating client challenges and macroeconomic uncertainties.

Click to open →

Get alerts for important filings

Add INDGN to your watchlist for board meeting & dividend alerts.

Open analysis →

News from yfinance + BSE corporate announcements. Importance scoring is automated. YieldIQ is not registered with SEBI as an investment adviser.